Investors
Corporate Profile
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.
Presentations
DateTitle
11/29/16
Dimension Therapeutics Corporate Presentation November 2016
Download Documentation
PDF
Stock
DMTX (Common Stock) $4.70 + 0.05 (1.08%)
High $4.85
Events
Dimension Therapeutics, Inc. 2016 Wells Fargo Healthcare Conference
09/08/16 3:30 p.m. ET
E-mail Alerts
Sign up to receive
E-mail Alerts
 
News
December 05, 2016
Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting
Researchers report the importance of capsid selection in AAV vector design and demonstrate that Clade E vectors have the highest levels of periportal liver gene transfer versus other serotypes CAMBRIDGE, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced an oral poster presentation that highlights find[...]  Read More /
November 29, 2016
Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
First COMP Positive Opinion for a Treatment in Development for GSDIa CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending DTX401 for designation as an orphan medic[...]  Read More /
November 10, 2016
Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results
Completed patient dosing in cohort 1 and dosing cohort 2 in ongoing Phase 1/2 trial with DTX101 for hemophilia B; clinical data expected in January 2017 IND filing and initiation of Phase 1/2 study for lead Inherited Metabolic Disease (IMD) program, DTX301 for OTC deficiency, anticipated by the end of 2016 Granted FDA orphan drug designation for DTX401 for glycogen storage disease type Ia (GSDIa) CAMBRIDGE, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX[...]  Read More /
Data provided by Nasdaq. Minimum 15 minutes delayed.